XLO
Xilio Therapeutics·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 0
Ample Liquidity
High Gross Profit Margin
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About XLO
Xilio Therapeutics, Inc.
A biotech company that develops tumor-selective immuno-oncology therapies for cancer
828 Winter Street, Suite 300, Waltham, MA 02451
--
Xilio Therapeutics, Inc., was incorporated in Delaware on June 18, 2020. The company is a biotechnology company focused on leveraging the immune system to achieve deep and durable clinical responses to improve the lives of cancer patients. The company has built geographically precise solutions, or GPS platforms, to rapidly design new molecules, including cytokines and biological agents, that are designed to optimize their therapeutic indices by geographically targeting their activity within the tumor. The company is advancing some geographically precise or tumor-selective drugs through different stages of development. The company also plans to continue to develop more immunotherapies using their GPS platform, including product candidates with a range of tumor-targeting approaches.
Company Financials
EPS
XLO has released its 2025 Q3 earnings. EPS was reported at -0.11, versus the expected -0.03, missing expectations. The chart below visualizes how XLO has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
XLO has released its 2025 Q3 earnings report, with revenue of 19.07M, reflecting a YoY change of 742.51%, and net profit of -16.29M, showing a YoY change of -16.17%. The Sankey diagram below clearly presents XLO's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
